The closing price of Hims & Hers Health Inc (NYSE: HIMS) was $13.04 for the day, down -2.18% from the previous closing price of $13.33. In other words, the price has decreased by -$0.29 from its previous closing price. On the day, 8258743 shares were traded.
Ratios:
Our analysis of HIMS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 56.51. For the most recent quarter (mrq), Quick Ratio is recorded 2.74 and its Current Ratio is at 3.00. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On February 26, 2024, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $10.
On December 07, 2023, Imperial Capital started tracking the stock assigning a In-line rating and target price of $9.Imperial Capital initiated its In-line rating on December 07, 2023, with a $9 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 27 when Becklund Irene sold 2,747 shares for $12.08 per share. The transaction valued at 33,184 led to the insider holds 5,494 shares of the business.
Boughton Soleil sold 5,972 shares of HIMS for $59,944 on Feb 15. The Chief Legal Officer now owns 154,345 shares after completing the transaction at $10.04 per share. On Feb 14, another insider, Dudum Andrew, who serves as the Chief Executive Officer of the company, sold 77,382 shares for $9.90 each. As a result, the insider received 766,268 and left with 51,653 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 2.86B and an Enterprise Value of 2.64B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.17 while its Price-to-Book (P/B) ratio in mrq is 8.09. Its current Enterprise Value per Revenue stands at 3.03 whereas that against EBITDA is -132.66.
Stock Price History:
Over the past 52 weeks, HIMS has reached a high of $13.91, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is 9.19, while the 200-Day Moving Average is calculated to be 8.09.
Shares Statistics:
HIMS traded an average of 3.49M shares per day over the past three months and 7.67M shares per day over the past ten days. A total of 205.10M shares are outstanding, with a floating share count of 134.79M. Insiders hold about 36.42% of the company’s shares, while institutions hold 38.97% stake in the company. Shares short for HIMS as of Feb 15, 2024 were 13.47M with a Short Ratio of 3.86, compared to 15.21M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.31% and a Short% of Float of 8.47%.
Earnings Estimates
The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.02 and a low estimate of -$0.04, while EPS last year was -$0.05. The consensus estimate for the next quarter is $0.01, with high estimates of $0.03 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.14 and -$0.11 for the fiscal current year, implying an average EPS of $0.05. EPS for the following year is $0.2, with 7 analysts recommending between $0.33 and $0.02.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $271.6M to a low estimate of $250.8M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $190.77M, an estimated increase of 39.80% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $282.74M, an increase of 37.90% less than the figure of $39.80% in the same quarter last year. There is a high estimate of $289.7M for the next quarter, whereas the lowest estimate is $260.1M.
A total of 11 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $1.2B, while the lowest revenue estimate was $1.07B, resulting in an average revenue estimate of $1.17B. In the same quarter a year ago, actual revenue was $878M, up 33.70% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $1.45B in the next fiscal year. The high estimate is $1.56B and the low estimate is $1.24B. The average revenue growth estimate for next year is up 23.50% from the average revenue estimate for this year.
